EVIDENCE LIBRARY
Midazolam as a CYP3A Probe Did Not Closely Predict Fentanyl Clearance in This Small Study
A palliative-care study found only a weak relationship between midazolam-based CYP3A activity and estimated fentanyl clearance.
A palliative-care study found only a weak relationship between midazolam-based CYP3A activity and estimated fentanyl clearance.
Testing a metabolic assumption
Twenty cancer patients receiving transdermal fentanyl had plasma measurements of fentanyl, norfentanyl, midazolam, and hydroxymidazolam. The investigators used midazolam metabolism as a CYP3A marker. Despite substantial variation in fentanyl concentrations, the clearance estimates were only weakly correlated.
A shared enzyme does not guarantee matching behavior
The study questions how much CYP3A variability explained fentanyl exposure in this selected clinical setting. Its small sample and real-world pharmacokinetic estimates constrain precision, and the finding does not mean CYP3A interactions never matter. Midazolam was a metabolic probe, not a tested treatment for pain. For interpreting a multidrug case, one drug’s clearance cannot simply substitute for another’s because both involve an enzyme. Distribution, delivery through a patch, other clearance processes, and patient illness may all be relevant.
Source paper
Original analysis of the supplied journal article, identified as PMC6786992.